The 2nd edition of FT US Pharma and Biotech Summit will provide a fresh perspective on the crucial issues impacting the pharma and biotech industries today. Senior industry leaders will share their insights, ideas and expertise on topics such as the pharma pricing and politics, the future of gene editing, tracking China’s pharma growth market and the opportunities and challenges of unconventional partnerships and collaborations across the new healthcare landscape.
FT US Pharma and Biotech Summit 2020
Pharma in the Age of Value and Affordability
Verily Life Sciences
With The Support Of
Global Clinical Research Partner
What attendees had to say about their 2019 experience
“This is a must-attend meeting for the healthcare industry. A thoughtfully curated agenda with industry leaders, emerging disruptors, patients and regulators makes this one of the top health events of the year.”
“The sessions highlighted the complexities that we have in the US healthcare system and the various viewpoints that we should all consider.”
“By far the most interesting summit to date. Basically stayed on topic and highlighted different views and perspectives effectively...”
Alexander Hardy became Genentech’s Chief Executive Officer on March 1, 2019. Previously, he was head of Global Product Strategy, Roche Pharmaceuticals and served in a number of key leadership positions across Genentech and Roche for over 13 years. Mr Hardy led cross-functional teams to develop and launch new medicines and indications in more than 100 countries worldwide. He also co-chaired Roche’s late-stage portfolio committee, with direct accountability for new formulations and devices, geographic expansion, and post-marketing investments. From 2014 to 2016, Mr Hardy was head of Asia Pacific for Roche Pharmaceuticals, overseeing 19 countries and more than 6,000 employees. Prior to this, starting in 2005 he held several senior management positions at Genentech, including heading patient access services and leading commercial operations for a range of medicines and therapeutic areas from HER2-positive cancer to influenza and neuroscience. Prior to Genentech, Mr Hardy held leadership positions at Novartis as head of market access for Europe, country head for Denmark, and business unit head and director of strategic planning and new product development in the UK. Mr Hardy completed his undergraduate education at Cambridge University in the UK and earned his MBA at the University of Michigan.
Sandy Macrae, MB, ChB, PhD, has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry, most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr Macrae held roles of increasing responsibility at GlaxoSmithKline (GSK), including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr Macrae received his BS in Pharmacology and his MB, ChB. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr Macrae also earned his PhD in Molecular Genomics at King’s College, Cambridge.
David Altshuler is Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals. Dr Altshuler leads Vertex’s research efforts aimed at discovering new medicines for the treatment of cystic fibrosis and other serious diseases, overseeing the company’s three research sites in the United States and Europe. Dr Altshuler was previously one of four founding members, Deputy Director and Chief Academic Officer at the Broad Institute of Harvard and MIT, a Professor at Harvard and MIT, and a physician at Massachusetts General Hospital. He was a leader of the SNP Consortium, HapMap and 1,000 Genome Projects, and his lab is credited with discovering over 100 gene variants associated with type 2 diabetes and other common diseases. A member of the National Academy of Medicine and the American Academy of Arts and Sciences, Dr Altshuler was named a Champion of Change by the White House for his leadership in creating and leading the Global Alliance for Genomic and Health.
Dr Peter Bach is a physician, epidemiologist, writer, and recognized expert in healthcare policy whose work has been regularly featured in major scientific and lay press outlets such as the NEJM, JAMA, and the New York Times. He is the Director, and currently holds the titles of Member in the Department of Epidemiology and Biostatistics and Attending Physician in the Department of Medicine at Memorial Sloan Kettering. He has also been a Senior Scholar at the International Agency for Research on Cancer since 2008.
Dr Bach is a member of the Institute of Medicine’s Board on Health Care Services and National Cancer Policy Forum and the Committee on Performance Measurement of the National Committee on Quality Assurance; he is also the Chair of the Center for Medicare and Medicaid Services Technical Expert Panel, which works to develop quality measures for PPS-exempt cancer hospitals. He has been inducted into the American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He also serves on the Board of Advisors of the University of Michigan Cancer Center and on the World Economic Forum, and is a member of the Clinton Global Initiative. Previously, Dr Bach was a member of the Institute of Medicine’s Committee on Geographic Variations and the Chair of a multi-society evidence-based guideline development committee on lung cancer screening. He also served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006
Dr Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar.
Tom Fezza is a Principal in Deloitte’s Life Sciences Strategy practice based in New York. He has over 20 years of consulting experience working with life sciences and health care companies. His areas of expertise include strategic planning, growth, R&D and therapeutic area strategy development, as well as operating model redesign.
Mr Fezza’s experiences are diverse, and range from defining and evaluating new business models, enterprise growth strategies, and commercialization strategies to assessing the performance and value of R&D organizations. He has worked with senior pharmaceutical, biotech, and health tech start-up leadership to successfully define and implement transformational strategies.
Mr Fezza is a graduate of the United States Military Academy at West Point. He also holds an MBA from the Wharton School at the University of Pennsylvania.
Oren Frank is a Co-founder and the CEO of Talkspace, the leading online and mobile psychotherapy company that has made therapy accessible and affordable to people across the globe. In a day and age when mental health care is recognized as a global societal crisis, the effectiveness and
convenience Talkspace provides to those seeking to improve their mental health and well-being stands out. Under Oren’s leadership, Talkspace has so far helped more than 500,000 clients connect with licensed therapists — the vast majority of whom had no prior access. As an avid believer in the
power of innovation and technology to better society, Mr Frank founded Talkspace with his wife Roni in 2012, with the vision of “Therapy for all.” After experiencing the benefits of couples therapy earlier in their marriage, they launched Talkspace with the strong belief that mental health care is a moral
right, and everyone should have access to the support and value psychotherapy provides whenever the need or want arises.
Prior to Talkspace, Mr Frank was a successful senior marketing and advertising executive, mostly with McCann Erickson WorldWide, where he was recognized as a progressive creative strategist, and one of the leading voices in the new media-marketing world. Mr Frank maintains that Talkspace helps him redeem and repent for his years spent in advertising.
Bernard Hamelin MD, MSc, MBA, is the Global Head of Medical Evidence Generation within the Medical Function at Sanofi, a global healthcare leader that discovers, develops and distributes therapeutic solutions for patients. In that role, he is responsible for delivering evidence required to demonstrate the value of Sanofi products, from early to late phase development. He also helps drive innovative and collaborative activities in order to engage with the changing healthcare landscape and to improve patient outcomes. Dr Hamelin is a Medical Doctor who trained in Liver diseases and Gastroenterology in Paris from 1984 to 1991. He joined AstraZeneca in 1991 as responsible for Gastrointestinal (GI) clinical and medical affairs programs in the company’s French affiliate. From 1994 to 2001 Dr Hamelin occupied different clinical research roles based in Sweden (Goteborg) and in the USA (Philadelphia). He was the lead physician on the esomeprazole (Proton Pump Inhibitor) project and led the emerging GI global product team. In 2001, Dr Hamelin was appointed head of the French AstraZeneca affiliate Medical Affairs team, based in Rue-Malmaison. His team supported the successful launch of different products (incl. Crestor (statin), Symbicort (inhaled glucocorticosteroid), Arimidex (aromatase inhibitor).
Richard Hanbury is the Founder of Sana Health, a neuromodulation platform for pain relief and deep relaxation. Mr Hanbury developed the technology behind Sana to eradicate his own life-threatening pain problem following a spinal cord injury from a jeep crash near Sana in Yemen in 1992.The original benchtop device removed all his nerve damage pain in 3 months, saving his life. He has spent 25 years developing the Sana technology from the original benchtop device to the current device undergoing clinical trials.Sana uses pulsed light and sound, and a heart rate variability feedback loop, to guide the user into a deep state of relaxation. Clinical trials have just been completed in Opioid Use Disorder and Fibromyalgia. Sana is launching in Fibromyalgia in 2020. Mr Hanbury has an MBA (Healthcare) from the Wharton School, and DipLaw (College of Law London)
Natalie Kofler is a trained molecular biologist and a leading voice in CRISPR and synthetic biology ethics. She advocates for equity in science and the inclusion of diverse perspectives in technology design and governance. Her work has been highlighted by The Guardian, Nature, CBC radio, Pacific Standard Magazine, and National Geographic. She is an affiliated scholar of the Yale Interdisciplinary Center for Bioethics and the Solomon Center for Health Law and Policy at the Yale Law School. She teaches Environmental Ethics and Justice at Harvard Medical School and Yale University. She received her PhD in cellular, molecular, and medical biosciences and MS in human nutrition and metabolic studies from Columbia University and her BS in human anatomy and cell biology from McGill University. Dr. Kofler is currently the Levenick Resident Scholar at the Institute of Sustainability, Energy, and the Environment at the University of Illinois Urbana-Champaign and founder of Editing Nature, a global initiative to steer responsible development and deployment of environmental genetic technologies.
An experienced entrepreneur and business leader, Ofer Leidner co-founded and built several digital media businesses, most recently iPlay/Oberon Media, a leading casual downloadable games company where he held several executive leadership roles. Mr Leidner has also served as Co-Founder and President of Gate42 Technologies, a software start-up in the customer relations management space. Earlier in his career, he served as an investment manager at an early stage seed fund and as a management consultant in the strategy practice of Trigger Consulting, a leading firm in Israel. Mr Leidner holds an MBA. in Finance and a BA in Economics and Information Technologies, both from Tel Aviv University.
William Lewis joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became Chairman of the board of directors in 2018. Mr Lewis is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the US and Europe. He also previously worked for the US government. Mr Lewis holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University.
Paul Levesque is responsible for a global organization of more than 1,250 colleagues who are focused on making a difference in the lives of those affected by rare diseases. His portfolio includes multiple medicines within multiple disease areas, including cardiomyopathy due to transthyretin amyloidosis, haematology, neuroscience, and inherited metabolic disorders. Additionally, alongside the Worldwide Research, Development and Medical (WWRDM) and Clinical Development Heads, Mr Levesque oversees a robust pipeline, which includes near-term opportunities in Sickle Cell Disease and longer-term opportunities with highly specialized, one-time gene therapy treatments for diseases that have single gene defects, such as certain neuromuscular and hematologic diseases. Mr Levesque has nearly 35 years of experience in the biopharmaceutical industry and has held several global senior leadership positions at Pfizer including, from 2016 to 2017, Global Marketing Head, Pfizer Essential Health, and from 2015 to 2016, Global President, Cardiovascular and Metabolic Business. Earlier roles included Regional President, APAC and China, Global Innovative Pharma from 2014-2015 and Regional President, Primary Care (Japan, Korea, Australia/NZ, and Canada) from 2013. Prior to this he served as Chief Marketing Officer, US Primary Care from 2007 to 2013 and as Country Manager and General Manager, Primary Care – Canada from 2007 to 2012. Mr Levesque holds a BSc in biochemistry from Laval University, Quebec City, and a Diploma in Management from McGill University, Montreal.
Husseini Manji, MD, FRCPC is Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, one of the Johnson & Johnson pharmaceutical companies. Dr Manji was previously Chief of the Laboratory of Molecular Pathophysiology & Experimental Therapeutics at the National Institutes of Health (NIH)and Director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world.The major focus of Dr Manji’s research is the investigation of disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. His work has helped to conceptualize these illnesses as genetically-influenced disorders of synaptic and neural plasticity and has led to the investigation of novel therapeutics for refractory patients. Most recently, his work contributed to the FDA approval of esketamine for treatment-resistant depression, an agent with the first novel mechanism of action in 60 years. Dr Manji has been inducted into the National Academy of Medicine (formerly IOM) and the World Economic Forum (WEF) Global Future Councils. He has received a number of prestigious awards, including the NIMH Director's Career Award for Significant Scientific Achievement, the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the DBSA Klerman Senior Distinguished Researcher Award, the American Federation for Aging Research Award of Distinction, and PhRMA’s Research & Hope Award for Excellence in Biopharmaceutical Research. He was also recognized as one of 14 inaugural “Health Heroes” by Oprah magazine.
John Oyler is Chairman and Co-Founder, and has served as Chief Executive Officer and a member of our Board of Directors of BeiGene since 2010. From 2005 to 2009, Mr Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology-focused biopharmaceutical company. Mr Oyler began his career as a management consultant at McKinsey & Company. Mr Oyler received his B.S. from Massachusetts Institute of Technology and MBA from Stanford University.
Veena Rao leads the External Innovation team at Eli Lilly and Company, with a focus on drug delivery, devices, digital health, and connected systems. Dr Rao’s team is responsible for the technical evaluations of new technologies, including novel delivery systems, devices, and software for Lilly’s core therapeutic areas including Diabetes, Immunology, Neurodegeneration, Pain, and Oncology. Previously, Dr Rao developed early customer experience solutions in support of Lilly’s diabetes devices. She has been at Lilly for 12 years and was previously a technology transfer officer at the University of Virginia with an emphasis in medical devices. Dr Rao gained a Ph in Chemical Engineering from Stanford and an MBA from the Darden School at the University of Virginia.
Mary Rozenman has more than 15 years of scientific expertise, company building and transactions leadership in the biotechnology industry. She is currently Chief Financial Officer/ Chief Business Officer of insitro, a company applying machine learning to drug discovery and development. There, she leads strategic and operational functions including finance and accounting, strategy, business development, investor relations and corporate communications, as well as project and portfolio management. Prior to Insitro, she was Senior Vice President of Corporate Development and Strategy at Aimmune Therapeutics, where she led business development and partnerships with companies such as Regeneron/Sanofi and Nestlé Health Science, and raised more than $650 million in capital through a range of private and public transactions including leadership of the company’s 2015 IPO. Before Aimmune, she was venture investor at Longitude Capital focused on biotechnology and a junior partner at McKinsey & Co focused on pharmaceuticals and corporate finance. Dr Rozenman holds a PhD in Organic Chemistry and Chemical Biology from Harvard University and a BA in Biochemistry and Russian literature from Columbia University.
Susan Shiff joined Merck in 2014 as Senior Vice President and head of the CORE organization. CORE links together epidemiologists, health economists, access and reimbursement scientists, health services researchers and others involved in health policy research with the goal of leading global strategic value evidence generation and access strategy development to optimize reimbursement and patient outcomes across Merck’s portfolio.
Prior to joining Merck, Dr Shiff was the Global Vice President, Health Economics Research and Evidence Based Medicine at Teva. Prior to Teva, she spent seven years at Pfizer, including several years as Vice President in the areas of outcomes research, epidemiology, health economics, and access and pricing. She has also led the global risk management group and US HEOR group at Roche and spent four years at the US Centers for Disease Control and Prevention (CDC).
Dr Shiff received her PhD degree from UCLA, and an MBA degree from Cornell University. She currently serves on the Institute for Clinical and Economic Review (ICER), Advisory Board and Methods Sub-Committee; Health Technology Assessment International (HTAi), Policy Advisory Board; the Innovation and Value Initiative (IVI), Panel of Health Advisors, the Academy of Managed Care Pharmacy (AMCP) Foundation Board, and the New Jersey Symphony Orchestra, Board of Trustees, Education, and Development Committees. She is also a Non-Executive Director of Synthace Ltd. In 2016, Dr Shiff was named one of the top 15 women in Biopharma by FiercePharma.
As the Co-founder and Executive Director of Patients Rising, Terry Wilcox helps patients find their voice and become outspoken advocates for their healthcare. She manages all of the day to day operations for the organization and is the visionary behind all of Patients Rising’s programs, including: Patients Rising University (education), Patients Rising Concierge (support), Institute for Patient Access & Affordability (research), and the policy and advocacy work of Patients Rising Now. She has a track record of building coalitions with patients, caregivers, and medical professionals. A regular opinion writer on health policy and how it affects patients, she has been published in the Boston Globe, The Hill, Morning Consult, Crains NY, Real Clear Health, the American Thinker, among others. Ms Wilcox’s career in patient advocacy was inspired by her mentor Selma Schimmel, considered by many as the “original” young adult survivor advocate. As Executive Director for Vital Options International, Ms Wilcox advanced Selma’s legacy at the non-profit cancer communication, education and advocacy organization. From 2008 to 2014, Ms Wilcox worked alongside Selma as Creative Director at Vital Options International and supervising producer for The Group Room.
Hui Wu, PhD is the founder of the International Co-Innovation Center for Advanced Medical Technology (iCCAMT) in Shanghai. With partners Medical Valley GmbH, Robert Bosch GmbH and SinoPharm (#169 on the FORTUNE Global 500), iCCAMT builds bridges between international healthcare players and China markets. Dr Wu is also Chair and Managing Partner in the China region for the Steinbeis Foundation, a German organization that promotes sharing of knowledge between universities and industry. Additionally, Dr. Wu is Venture Partner at Charoen Pokphand (CP) Asset Management, a life sciences investment fund from CP Group, Thailand’s largest company, and Senior Advisor to the Chairman at CP Pharma, parent company of Sino Biopharmaceutical Ltd, which is listed on the Hong Kong Stock Exchange. Dr Wu previously served for several years as a vice division leader for AVIC International, a leading Chinese state-owned enterprise with annual revenue of over US$50bn. Dr Wu holds a BSc in Biology from Wuhan University in China, a Master’s degree in Biomedicine from Uppsala University in Sweden and a PhD in cancer genomics from the University of Heidelberg in Germany.
Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York. Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.
Sarah Neville is Global Pharmaceuticals Editor of the Financial Times, a position she has held since 2016. She joined the Financial Times in 2001 and has held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and Public Policy Editor. She began her career on local and regional newspapers, eventually becoming Political Editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post.
Agenda - 14th May
8:15amRegistration & Breakfast
9:00amOpening Remarks from the Chair
9:05amKeynote Address/ Interview
9:20amPanel: Pharma Pricing and Politics: From Rhetoric to Action?
The issue of rising drug prices remains front and centre of the political debate in the 2020 election year. A host of proposals have been put forward in recent months by the Senate Finance Committee, House Democrats and the White House to hold the pharma industry ‘accountable for its actions’. If some of the more hard-hitting measures come to light, the implications for the underlying economic model of the industry are potentially profound.
- What is the good, the bad and the ugly of the multitude of proposed reforms on the table? What are the proposals which could have a meaningful impact on drug prices?
- How are value-based pricing deals evolving and what impact could they potentially have on drug pricing?
- Are subscription models the way ahead for paying for one-time cures?
- Should patent reforms and attempts to address ‘evergreening’ and ‘patent thickets’ play a bigger role of the debate?
Peter Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
Terry Wilcox, Co-Founder and Executive Director, Patients Rising
Tom Fezza, Partner Life Sciences and Health Care Strategy Advisor, Deloitte
10:10amKeynote Interview/ Address
Alexander Hardy, CEO, Genentech
10:25amPanel: Mission Critical: Unlocking the Potential of Real-World Evidence ( RWE) / Real-World Data (RWD)
Real-World Evidence (RWE) is increasing in use and importance across the pharma and broader healthcare industry. Key drivers include the growing willingness to include RWE in regulatory decision-making, the extension of value-based pricing, as well as a mounting awareness of the strategic benefits RWE can bring in terms speedier and more efficient drug development, enhanced patient engagement and competitive edge in an ever more value driven, personalized healthcare system. Yet many barriers - both internal and external - exist before the full potential of RWE/RWD can realised.
- As the landscape for RWE continues to evolve, what are the implications for current infrastructure, governance, operating models, people and processes of pharma companies?
- What are the learnings and insights of market leaders who have developed end-to-end RWE /RWD capabilities?
- How is the data landscape evolving?
Susan Shiff, Senior Vice President and Head of Center for Observational and Real-World Evidence (CORE), Merck
Bernard Hamelin, Global Head of Medical Evidence Generation, Sanofi
Everett Neville , Senior Vice President, Value Creation , Cigna
11:05amNetworking Coffee Break
11:25amKeynote Address/ Interview
Jessica Mega, Chief Medical and Scientific Officer, Verily Life Sciences
11:40amBridging a Pharma-Digital Divide? Unconventional Partnerships and Collaborations in Pharma
As pharma companies navigate the new world of digital and value, they are working in close partnerships with players from the world of big tech and big data. Among the many benefits, these relationships allow pharma companies to leverage expertise and talent, build closer relationships with patients and gain a foothold in the fast-growing business of digiceuticals and AI-driven products and services. Yet it is often remarked that an unspoken divide separates the ‘parallel worlds’ of pharma and tech, preventing closer alignment and realizing the full potential that such partnerships can offer. The ‘glacial pace of decision-making’ and siloed world of in pharma is often contrasted with the more ‘agile and open’ world of tech.
- How real is the ‘cultural divide’ between pharma and data companies? What have been the experiences of such partnership to date? How synergistic are the relationships?
- How are pharma companies and their digital partners navigating challenges of IP, data rights, sharing and ownership and attributing value in such joint endeavours? How are partnership models evolving?
- How vital are partnerships: could pharma ‘go it alone’ on AI and digital therapeutics?
Daphne Koller, CEO and Founder, Insitro
Ofer Leidner, President and Co-Founder, Happify Health
Veena Rao-Mirmira, Vice President, External Innovation, Eli Lilly and Company
Moderator: Mike DeLone, Principal, US Life Sciences Sector Leader, Deloitte
12:20pmKeynote Address/ Interview
William Lewis, Chairman and CEO, Insmed
2:05pmPanel: New Approaches for a New Age in Mental Health
Over 46 million Americans suffer from mental illness, yet difficulties experienced in gaining access to treatment specialists and a dearth of new psychiatric drugs has left patients with ever more limited treatment options. The cost and complexity of research in the field of mental illness has seen the withdrawal of big pharma from the field of psychiatric drug research over the past decades. Yet new research in the field of genomics and mental health and in emerging areas to include immunemodality drugs, psychedelics and beyond, as well as new efforts to better understand the biology of the brain and mental illness hold the promise of new drugs in the future. Meanwhile, a new wave of apps and other digital interventions are rapidly changing the way mental health care is delivered, extending delivery beyond pills and traditional, in-person sessions to offer around-the-clock support from remote physicians or tech-driven tools that reach the patient wherever they are. Healthcare providers and pharma companies alike are looking increasingly to provide digital mental health offerings, often in partnership with start-ups.
- What might be the next leap forward in psychiatric pharmacology?
- What is the potential for genomics in mental health?
- What are the advances in our understanding of biology of the brain and mental health which hold the promise for new drugs?
- What is the potential and the challenges (e.g dealing with high-risk scenarios) with the new generation of digital apps and treatments?
Oren Frank, Co-Founder and CEO, Talkspace
Husseini Manji, Global Therapeutic Head for Neuroscience, Janssen Research & Development
2:35pmInnovation Showcase/ Breakthrough Science: Beyond Opioids - Next Frontiers in Pain Medicine and Management
A contributing factor to the opioid crisis which has paralysed America and is now being felt in a growing number of countries is the absence of effective alternatives to pain modification and management. Despite current therapeutics and interventions, pain continues to pose a significant burden to patients and the healthcare system on a global scale. The number of adults living with chronic pain in the United States annually exceeds those living with cancer, diabetes and heart disease combined, and approximately one quarter of these people endure severe pain on a daily basis. Here we highlight one of the emerging innovations in alternative, non-opioid pain medicines and therapies and review the market potential.
Richard Hanbury, Founder, Sana Health
3:00pmNetworking Coffee Break
3:20pmPanel: Leader or Follower? Tracking China's Pharma Growth
China is stepping up its investment in life sciences and is aiming to take a lead in drug development, AI, gene editing and gene therapies. It is also now the second largest pharmaceuticals market in the world and is set to be the first within 7-10 years. Recent moves by the industry regulator are paving the way for faster drug approvals and greater access for patients to advanced therapies. Meanwhile, China is embracing digital at a pace which eclipses the efforts in most other countries, and lacking the burden of legacy primary health care systems, is creating innovate new treatment and service models. Having a strategic presence in China is now as paramount. In the immediate term, however, a looming trade war and the impacts of restrictive foreign investment rules in the form of CIFUS are expected to play a moderating role on the potential for closer US-China life science collaboration. What is the true potential of innovative drug development in China? If China’s innovator drugs can undercut US prices, should the global industry be on notice?
John Oyler, CEO, BeiGene
Hui Wu, Venture Partner, Chareon Pokphand Asset Management
4:10pmThe Future of Cell and Gene Therapies
The excitement surrounding the potential of cell and gene therapies continues with important new developments underway. After developing the first gene therapies for rare diseases, biotech companies are seeking to extend gene treatments to common illnesses affecting millions of people, providing new competition for big pharma in the process. Meanwhile, with the advent if the first human in-body gene editing, we are entering a new stage in the gene editing revolution that could lead to more diseases being treated or cured with this technology. However, many questions remain unanswered.
- The new therapies look transformational, but will they be commercially successful for pharma given the manufacturing, administration, reimbursement and other complexities?
- How can we industrialize personalisation to ensure sustainable patient access to advanced therapies?
- How could the ‘engineering’-based approach of gene editing potentially transform the business of pharma?
- Can the safety and ethical concerns surrounding gene editing be addressed? Where do we draw the line between risk and opportunity?
David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer, Vertex Pharmaceuticals
Paul Lévesque, Global President, Rare Diseases, Pfizer
Sandy Macrae, President and Chief Executive Officer, Sangama Therapeutics
Natalie Kofler, Founder, Editing Nature
5:00pmClosing Remarks from the FT Chair
Companies in attendance in 2019
Sanofi • FDA • Eisai • Bayer • AstraZeneca • Novartis Pharmaceuticals • Mylan • Otsuka • GlaxoSmithKline • Eli Lilly • Pfizer • National Pharmaceutical Council • Takeda • UCB • Janssen • Vitruvian Biomedical • Bristol Myers Squibb • BioMarin Pharmaceutical Inc • Aquestive Therapeutics • Johnson & Johnson • Ibex Biosciences • Bound Therapeutics LLC • Horizon Pharma • Spark Therapeutics • Celgene • Regeneron Pharmaceuticals • CONTINUUS Pharmaceuticals and many others.
The FT US Pharma & Biotech Summit will be attended by CEOs, CFOs, CTOs CIOs, Head of R&D, Chief Medical Officers, Chief Strategy Officers, Chief Digital Officers, Market Access and Pricing, Chief Business Officers and other senior-level executives in the following sectors:
- Pharmaceutical & Biotechnology Companies
- Pharmaceutical Wholesalers/PBMs
- Healthcare insurers and government payers
- Government healthcare departments and agencies
- IT, big data and analytics providers
- Medical Device Manufacturers
- Investment bankers, private equity and VCs
- Patient representatives and health-related NGOs
- Gain access to 250 executives and leaders from across the US pharmaceutical industry;
- Brand alignment with the FT and its unrivalled credibility;
- Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
- Benefit from sustained international visibility through our advertising and marketing campaigns
Head of Portfolio
- Gain insights into the healthcare reforms being proposed by US Presidential candidates and how they might affect pharma pricing and risk
- Hear how payer’ perspectives on value is evolving
- Discuss the challenges and opportunities of unconventional partnerships in pharma and the myth and reality of pharma’s digital divide
- Debate whether governments should play a bigger role in drug development as ROI diminishes, shortages increase and price of drugs continue to rise
- Get the inside story on whether China will be a leader or follower in life sciences as the county’s level of ambition and innovation increases
- Discover the latest development in gene editing and have your say on where we should draw the line between risk and opportunity
PRESENTED BY (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.
With the support of (1)
About Life Sciences and Health Care at Deloitte
Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
Global Clinical Research Partner (1)
ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.
ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.
With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 40 countries and has approximately 14,500 employees. For further information please visit www.iconplc.com Follow @iconplc on Twitter.
Lead Sponsor (2)
Associate Sponsors (2)
Livongo offers a whole person platform that empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including hypertension, weight management, diabetes prevention, and behavioral health. Livongo pioneered the new category of Applied Health Signals to silence Noisy Healthcare™. Our team of data scientists aggregate and interpret substantial amounts of health data and information to create actionable, personalized and timely health signals. The Livongo approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions.
TraceLink is a network-based platform company that leverages its digital supply network and digital network platform to bend the supply chain around the patient. Through its industry-leading digital supply network, the TraceLink Digital Network Platform can enable seamless data sharing and process orchestration across the entire healthcare industry, enabling the creation of a real-time, patient-driven supply network to ensure that every patient gets the medicines they need, when they need them, safely and securely.